Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX Reports Q3 Revenue of $1.2B and Raises Full-Year 2026 Guidance

Positive Impact 4 of 5 earnings

IDEXX Laboratories announced third-quarter revenue of $1,214 million and diluted earnings per share of $4.01, representing solid year-over-year gains. Driven by strong Companion Animal Group performance and innovation adoption, the company raised its full-year 2026 revenue and EPS outlook for shareholders.

Key points

  • Third-quarter revenue reached $1,214 million, up 10% as reported and organic.
  • Diluted earnings per share were $4.01, an increase of 18% as reported.
  • Full-year 2026 revenue guidance was updated to a range of $4,741 million to $4,767 million.
  • Full-year 2026 EPS outlook was raised to $14.96 to $15.16.

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECNov 2, 2026, 6:30 AM ET
Accession number0001104659-26-120892

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 2, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.